Betta Pharmaceuticals Co., Ltd. Class A 300558
SZSE · China · Health Technology
CNY 50.48+1.52 (+3.10%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Xcovery Holdings, Inc., (Xcovery) an evidence-based, innovation-driven pharmaceutical company, today announced an agreement with EVERSANA®, a leading provider of commercialization services to the global life sciences industry, to support and expand the U.S. commercial launch of ENSACOVE™ (ensartinib), the company's novel therapy for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical - known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) - and profitable cancer-drug developer Betta Pharmaceuticals. Other initial public offe
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.